medigraphic.com
ISSN 1608-8921 (Impreso)

2011, Número 3

<< Anterior Siguiente >>

Gaceta Médica Espirituana 2011; 13 (3)


Criptococosis. Una amenaza para pacientes inmunodeprimidos

García CJL, Novoa LAM

Idioma: Español
Referencias bibliográficas: 43
Paginas:
Archivo PDF: 383.67 Kb.


RESUMEN

Fundamento: La infección criptococócica, micosis oportunista que solía ser fatal en inmunodeprimidos, ya no es una sentencia de muerte ineludible después de la expansión de los tratamientos antirretrovirales pero sigue afectando, sobre todo a los países en vías de desarrollo. Objetivo: Profundizar los conocimientos sobre la criptococosis en su tratamiento y evolución porque es un flagelo que agrava y mata a los pacientes de sida o inmunodeprimidos. Conclusiones: Queda a los médicos de asistencia, el diagnóstico precoz y el tratamiento oportuno e individualizado de la criptococosis, para cumplimentar su objetivo: devolver salud y calidad de vida a los seres humanos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Goldman L, Ausiello D. Cecil. Tratado de Medicina Interna. 23ra ed. España: Eselvier SA; 2009.

  2. Jawetz E, Melnick JL, Adelberg EA. Microbiología Médica.14ta ed. La Habana: Ecimed; 2006.

  3. Llops V, Dapena Z. Microbiología y Parasitología médicas. La Habana: Ecimed; 2001.

  4. Beers M, Porter R, Jones T, Berkwits M. El Manual Merck. 11na ed. La Habana: Ecimed; 2007.

  5. Dromer F, Mathoulin PS, Launay O, Lortholary O. Determinants of Disease presentation and outcome during cryptococcosis: the Crypto A/D study. PLoS Med. 2007 Feb;4(2):e21. Available from: http://preview.ncbi.nlm.nih.gov/pmc/articles/PMC1808080/?tool=pubmed

  6. Leal AL, Faganello J, Fuentefria AM. Epidemiological profile of cryptococcal meningitis patients in Rio Grande do Sul, Brazil. Mycopathologia. 2008 Aug;166(2):71-5. Available from: http://www.springerlink.com/content/80512 p61455q0654/

  7. Muñoz P, Giannella M, Valerio M, Soria T, Díaz F, Longo JL, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis. 2007 Apr;57(4):443-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17240111

  8. Tuxen AJ, Yong MK, Street AC, Dolianitis C. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin. Br J Dermatol. 2007;157:1067-1068. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2007.08171.x/abstract

  9. Wilson ML, Sewell LD, Mowad CM. Primary cutaneous cryptococcosis during therapy with methotrexate and adalimumab. J Drugs Dermatol. 2008 Jan;7(1):53-4. Available from: http://www.hopkinsguides.com/hopkins/ub/citation/18246698/Primary_cutaneous_Cryptococcosis_during_therapy_with_methotrexate_and_adalimumab_

  10. Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infec Dis. 2007 Jun;44(12):e115-7. Available from: http://cid.oxfordjournals.org/content/44/12/e115.long

  11. Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving antithymocyte globulin or alemtuzumab. Transpl Infect Dis. 2007 Mar;9:22-27. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1399-3062.2006.00149.x/abstract;jsessionid=47BCEE4F8A483381915E0F340EE9092

  12. Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. Cryptococcus gattii risk for tourists visiting Vancouver Island, Canada. Emerg Infect Dis. 2007 Jan;13(1):178-179. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725802/

  13. Galanis E, MacDougall L, Li M, et al. Clinical and epidemiological aspects of locally-acquired Cryptococcus gattii human infections, an emerging fungal pathogen in British Colombia, Canada [Abstract O170]. In: Proceedings of the 17th ECCMID. Munich: 2007. Available from: http://www.blackwellpublishing.com/eccmid17/PDFs/clm_1732.pdf

  14. Wong ML, Back P, Candy G, Nelson G, Murray J. Cryptococcal pneumonia in African miners at autopsy. Int J Tuberc Lung Dis. 2007 May;11(5):528-33. Available from: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/65789222.1/iuatld/ijtld/2007/00000011/00000005/art00010/CEF994352E26D78A1321904562D58BE63804294C80.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf

  15. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med. 2008 Apr;29(2):141-50. Available from: https://www.thieme-connect.com/DOI/DOI?10.1055/s-2008-1063853

  16. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer A, Loyse A, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008 Jul 1;47(1):123-30. Available from: http://cid.oxfordjournals.org/content/47/1/123.long

  17. Brouwer AE, van Kan HJ, Johnson E, Rajanuwong A, Teparrukkul P, Wuthiekanun V, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother. 2007 Mar;51(3):1038-42. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1803146/?tool=pubmed

  18. Dromer F, Bernede Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One. 2008 Aug;3(8):e2870. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483933/?tool=pubmed

  19. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 2006 Jan;50(1):113-20. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1346792/?tool=pubmed

  20. Schwarz P, Janbon G, Dromer F, et al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 2007 Jan;51(1):383-5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797681/?tool=pubmed

  21. Pappas PG, Nolen T, Chetchotisakd P, Larsen R, Manosuth W,Filler S. Fluconazole plus Amphotericin B vs. Amphotericin B alone for primary treatment of AIDS-associated cryptococcal meningitis: results of a phase II trial. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago: 2007. Available from: http://www.mindcull.com/data/american-society-for-microbiology/icaac-2007-antimicrobial-agents-and-chemotherapy/fluconazole-flu-plus-amphotericin-b-amb-versus-amb-alone-for-primary-treatment-of-aids-associated-cryptococcal-meningitis-cm-results-of-a-phase-ii-trial/

  22. Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol. 2008 Jun;46(4):393-5. Available from: http://informahealthcare.com/doi/abs/10.1080/13693780701851695

  23. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviralexperienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):76-80. Available from: http://cid.oxfordjournals.org/content/45/1/76.full.pdf

  24. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIVassociated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis. 2006 Oct 15;43(8):1069-73. Available from: http://cid.oxfordjournals.org/content/43/8/1069.long

  25. Segal BH, Kwon Chung J, Walsh TJ, Klein BS, Battiwalla M, Almyroudis NG, et al. Immunotherapy for fungal infections. Clin Infect Dis. 2006;42:507-15. Available from: http://cid.oxfordjournals.org/content/42/4/507.long

  26. Hamill RJ, Sobel JD, El Sadr W, Johnson PC, Graybill JR, Javaly K, et al. Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS-Associated Acute Cryptococcal Meningitis: A Randomized, Double-Blind Clinical Trial of Efficacy and Safety. Clin Infect Dis. 2010;51(2):225-232. Available from: http://www.revneurol.com/sec/RSS/noticias.php?idNoticia=2305

  27. Siddiqui AA, Brouwer AE, Wuthiekanun V, Jaffar S, Shattock R, Irving D, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005;174(3):1746-1750. Available from: http://www.jimmunol.org/content/174/3/1746.full.pdf

  28. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis. 2005 Jan;51(1):19-29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15629225

  29. Manosuthi W, Sungkanuparph S, Chottanapund S, Tansuphaswadikul S, Chimsuntorn S, Limpanadusadee P, et al. Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS. 2008 Apr;19(4):268-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18482948

  30. Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, Dousset JP, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007 Aug;45(5):555-9. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/17577124

  31. Lawn SD, Harries AD, Anglaret X, Myer L, Word R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908. Available from: http://www.who.int/hiv/events/artprevention/lawn_early.pdf

  32. Etard JF, Ndiaye I, Thierry Mieg M, Guèye NF, Guèye PM, Lanièce I, Etard JF, Ndiaye I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006 May 12;20(8):1181-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16691070

  33. Kambugu A, Castelnuovo B, Wandera B, et al. Antiretroviral therapy in an urban African cohort does not prevent significant early mortality [Abstract 055]. In: Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney: International AIDS Society; 2007.

  34. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. 2007 Nov;55(5):464-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17714788

  35. Harling G, Orrell C, Wood R. Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res. 2007;7:80. Available from: http://www.biomedcentral.com/1472-6963/7/80

  36. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John G, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis. 2008;46(2):e12-e18. Available from: http://cid.oxfordjournals.org/content/46/2/e12.short

  37. Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005 Jul 1;19(10):1043-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15958835

  38. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):595-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17704683

  39. Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med. 2007 Dec 13;357(24):2441-50. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa065711

  40. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. South Afr J HIV Med. 2007;28:25-35. Available from: http://www.kznhealth.gov.za/medicine/cryptoguidelines.pdf

  41. Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. J Med Assoc Thai. 2006 Jun;89(6):795-802. Available from: http://preview.ncbi.nlm.nih.gov/pubmed?term

  42. Manosuthi W, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviraltherapy and fluconazole. BMC Infect Dis. 2007;7:14. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1828732/?tool=pubmed

  43. Harrison. Principios de Medicina Interna. 17a ed. New York: McGraw-Hill; 2010. Available from: http://www.harrisonmedicina.com/content.aspx?aid=3729665




2020     |     www.medigraphic.com